A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3002813 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
Phase of Trial: Phase I
Latest Information Update: 29 Dec 2017
Price : $35 *
At a glance
- Drugs Donanemab (Primary) ; Donanemab (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Eli Lilly
- 21 Dec 2017 Status changed from active, no longer recruiting to completed.
- 20 Sep 2017 Planned End Date changed from 1 Aug 2017 to 1 Nov 2017.
- 20 Sep 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Nov 2017.